FDA accepted, for priority review, supplemental Biologics License Applications for Padcev (enfortumab vedotin-ejfv) and Keytruda (pembrolizumab) for use of these two agents in combination for the treatment of patients with locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-containing chemotherapy.
For a decade, thousands of PhDs in epigenetics may have been relying on the wrong tool as they study the biological processes that regulate how and when genes are expressed or silenced.
